TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
CAMBRIDGE, Mass., May 07, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that it will host a conference call and webcast on Monday, May 14, 2018, at 5:00 p.m. ET to report financial results for the first quarter 2018 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7589367. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
[email protected]
617-680-1088
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia
[email protected]
212-362-1200
